[Our experience with o,p'-DDD in the treatment of hypercorticism].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000311:Adrenal Glands / Q000187:drug effects; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy*; D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003480:Cushing Syndrome; D003632:Dichlorodiphenyldichloroethane / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D009336:Necrosis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000150:complications; D011300:Preoperative Care; D013237:Stereoisomerism
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D002784:Cholesterol; D003632:Dichlorodiphenyldichloroethane; D006854:Hydrocortisone
Notre expérience de l'op'DDD dans le traitement des hypercorticismes.